Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25182554 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL199585 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL8639706 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL25185567 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL6761849 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL25185557 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL5682734 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL199452 | 0.98 | ALDH1A1 (0.41) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL5984758 | 0.93 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL5985735 | 0.93 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| EP-4180041-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11596629-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-12-29 | — | — | US | disclosed |
| US-11325892-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3808349-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3177292-B1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200061055-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-02-27 | — | — | US | disclosed |
| CN-1009554-B | RHIZOXIN DERIVATIVES AND ITS PROCESS FOR PREPARING THE SAME | SANKYO CO (JP) | 1990-09-12 | — | — | CN | disclosed |
| CN-1042153-A | 3-aryloxy methyl-cephalosporins derivatives, their preparation and purposes pharmaceutically | SANKYO CO (JP) | 1990-05-16 | — | — | CN | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| CN-1040982-A | Nitragin (rhizoxin) derivative and as antineoplastic agent | SANKYO CO (JP) | 1990-04-04 | — | — | CN | disclosed |
| CN-1040196-A | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | SANKYO CO (JP) | 1990-03-07 | — | — | CN | disclosed |
| EP-0353047-A2 | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | Sankyo Company Limited (JP) | 1990-01-31 | — | — | EP | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4791128-A | Rhizoxin esters and salts, their pharmaceutical use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1988-12-13 | — | — | US | disclosed |
| EP-0218310-A2 | Rhizoxin derivatives, their preparation and pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1987-04-15 | — | — | EP | disclosed |
| CN-86102020-A | The preparation method of rhizoxin derivatives and in pharmaceutically application | — | 1986-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325892-B2 | Compounds and methods for treating cancer | SCD, CPT1B, CPT1A | ALDH1A1 287/4885TDP1 1349/4885LMNA 1768/4885 |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | ALDH1A1 287/4885TDP1 1349/4885LMNA 1768/4885 |
| US-11596629-B2 | Compounds and methods for treating cancer | SCD, SCD5, CPT1B | ALDH1A1 255/4885TDP1 877/4885LMNA 2601/4885 |
| US-20200061055-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | ALDH1A1 255/4885TDP1 877/4885LMNA 2601/4885 |
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | ALDH1A1 255/4885TDP1 877/4885LMNA 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.